Ramius dangles higher offer for Cypress Bioscience
This article was originally published in Scrip
Executive Summary
Ramius LLC has stepped up the pressure on acquisition target Cypress Bioscience, reiterating its $4.00 per share takeover offer and dangling the possibility of an improved offer if Cypress is prepared to negotiate and let Ramius have a closer look at its finances.